respiratory-syncytial-virus

Documents about respiratory-syncytial-virus

• A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV#897359ClinicalTrials.gov
• A Phase II Clinical Study to Evaluate the Efficacy and Safety of YKYY018 for Inhalation Solution#863126ClinicalTrials.gov
• Epidemiology and factors associated with respiratory syncytial virus in patients with severe acute respiratory illness in Amhara Region, Northwest Ethiopia#339226Springer Nature OA
• Investigation of maternal outcomes following respiratory syncytial virus vaccination in the third trimester: insights from a real-world United States electronic health records database.#151472NCBI PubMed Central
• Burden of Respiratory Syncytial Virus Infection in Immunocompromised Adults: A Systematic Review of the Evidence From High-Income Countries#456074Springer Nature OA
• RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness#478502Europe PMC
• An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults#332805ClinicalTrials.gov
• Meta-analysis of the efficacy of palivizumab versus nirsevimab at preventing medically attended respiratory syncytial virus infections in non-hospitalized preterm infants#4493Europe PMC
• A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers#230487ClinicalTrials.gov
• Point-of-Care Nucleic Acid Amplification Tests for Respiratory Syncytial Virus Detection in Children and Adults: A Systematic Literature Review#237340Springer Nature OA
• Effectiveness of Nirsevimab on Primary Care Visits for Respiratory Syncytial Virus–Associated Acute Otitis Media in Infants#261975HAL (France)
• The Clinical and Symptomatic Burden Among Older Adults with Respiratory Syncytial Virus: A Real-World Survey in Five European Countries#355780Springer Nature OA
• A Study of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to 75 Years#390955ClinicalTrials.gov
• The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy#260116IRIS
• Hospitalisation Burden of Human Metapneumovirus and Respiratory Syncytial Virus in Adults by Age and Comorbidity Status in Scotland: A Retrospective Analysis#456068Springer Nature OA
• A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.#854714ClinicalTrials.gov
• Reduced inflammatory and Th1 transcriptional profiles in geriatric versus adult cotton rats infected with respiratory syncytial virus#355221PLOS
• Comparison of the Hospital Burden Associated with Respiratory Syncytial Virus and Human Metapneumovirus Across All Age Groups in Scotland: A Retrospective Analysis#456069Springer Nature OA
• Analysis of the Economic and Public Health Impact of New Immunization Strategies in Infants Against Respiratory Syncytial Virus (RSV) in Colombia#456070Springer Nature OA
• A strategic blueprint for strengthening respiratory syncytial virus prevention among under-five children in low- and middle-income countries: Bangladesh as a model for new immunisation approaches.#265445NCBI PubMed Central
• Evaluation of Chest Physiotherapy for Acute Bronchiolitis in Toddlers (BRONKINOU)#913147ClinicalTrials.gov
• Healthcare resource use and costs following RSV-related hospitalizations among US adults aged 50 years and older#970727Europe PMC
• Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections#914695ClinicalTrials.gov
• A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants#125948ClinicalTrials.gov
• A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy#279558ClinicalTrials.gov
• A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection#405190ClinicalTrials.gov
• Burden of Respiratory Syncytial Virus in Older ADults in Nagasaki, Japan (Nagasaki ROAD): Preliminary Results (April 2024–March 2025) of a Prospective, Multicenter, Epidemiological Study#145133Springer Nature OA
• Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019–2023 national databases: A retrospective study#400852Repositorio Académico de la Universidad de Chile
• A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older#405199ClinicalTrials.gov
• A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers#651131ClinicalTrials.gov
• Acceptability and preferences regarding RSV immunisation during pregnancy: a cross-sectional study in diverse global settings#311941HAL (France)
• Second-season Impact of Nirsevimab: Clinical Outcomes of RSV Disease in Patients Immunized During Their First Season.#672219Repisalud
• Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children#851118ClinicalTrials.gov
• Human respiratory syncytial virus infects and induces activation markers in mouse B lymphocytes#646710Repisalud
• Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults#832425ClinicalTrials.gov
• Real-world evidence on RSV vaccine uptake, effectiveness, and safety in older adults: a systematic review and meta-analysis#5394Europe PMC
• Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial#205423Europe PMC
• Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration.#672217Repisalud
• Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children#896160ClinicalTrials.gov
• Household Study of COVID-19, Influenza and RSV Burden, Transmission Dynamics and Viral Interaction in South Africa#993126ClinicalTrials.gov
• Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age#883875ClinicalTrials.gov
• Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life#1010060ClinicalTrials.gov
• Clinical presentation and hospitalisation risk of RSV in primary care among children younger than 5 years in Italy in four seasons between 2019 and 2023: a multicentre prospective cohort study#5225Europe PMC
• Pregnancy and Infant PrEparedness pLatform IN Europe, RSV-International Adaptive Platform Trial to Evaluate Two Approved Prevention Options to Prevent Respiratory Syncytial Virus in Infants: Maternal Vaccine to Women in Pregnancy and Monoclonal Antibody to the Infants, Given Alone or in Combination.#353335ClinicalTrials.gov
• 5C psychological antecedents of vaccine hesitancy toward maternal RSV vaccines and infant monoclonal antibodies among pregnant and postpartum women and their partners in China: A multicenter, dyadic survey design, cross-sectional study#784386Europe PMC
• Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults#915896ClinicalTrials.gov
• A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.#28417ClinicalTrials.gov
• A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health#353338ClinicalTrials.gov
• Contemporary dialogues in health sciences#928238Repositório Institucional da UFMG